Kura Oncology (KURA) announced the upcoming presentation of new preclinical data supporting the combination of its next-generation farnesyl transferase inhibitor, FTI, KO-2806 with targeted therapies, including KRASG12C inhibitors and pan-RAS inhibitors, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. “We look forward to presenting an update to our growing body of preclinical and clinical data that demonstrate the potential of KO-2806 as a companion therapeutic to augment the antitumor activities of KRASG12C and pan-RAS inhibitors,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KURA:
- Kura Oncology initiated with an Outperform at LifeSci Capital
- Kura Oncology downgraded to Hold from Buy at Stifel
- Kura Oncology announces Ziftomenib Phase 1 results in The Lancet
- Kura Oncology Welcomes New Director Michael Vasconcelles
- Kura Oncology appoints Vasconcelles to board of directors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
